On June 22, 2023, Board of Directors of Regulus Therapeutics Inc. appointed Preston S. Klassen, M.D., President and Head of Research & Development, to the Board, to serve until next annual meeting of stockholders and until his successors is duly elected and qualified, or until his earlier death, resignation or removal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | +6.61% | +13.62% | +89.06% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.06% | 158M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RGLS Stock
- News Regulus Therapeutics Inc.
- Regulus Therapeutics Inc. Appoints Preston S. Klassen to the Board